Denali Therapeutics announced the pricing of its underwritten public offering of 9,142,857 shares of common stock at $17.50 per share.
In addition, pre-funded warrants are being offered to certain investors to purchase 2,285,714 shares of common stock at $17.49 per warrant.
The company expects to receive gross proceeds of approximately $200 million before deducting underwriting discounts.
Offering Details
9,142,857 shares of common stock priced at $17.50 per share and 2,285,714 pre-funded warrants offered at $17.49 per warrant.
Underwriters
Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, and Jefferies LLC are acting as joint book-running managers.
Closing Date
The offering is expected to close on or about December 11, 2025, subject to customary closing conditions.
- Denali Therapeutics aims to raise capital through this offering to support its development initiatives for neurodegenerative and lysosomal storage diseases.
- The successful pricing indicates investor interest in the company's proprietary TransportVehicle™ platform and therapeutic candidates.
The pricing of the public offering and pre-funded warrants marks a significant milestone for Denali Therapeutics in advancing its mission to deliver effective medicines for serious diseases.